Loading
institutionsInstitution
National Taiwan University Hospital
Taiwan's leading academic hospital and the birthplace of the hepatitis B vaccination programme that cut childhood liver cancer, with a new dedicated cancer centre.
Also called: NTUH臺大醫院National Taiwan University Cancer Center
Overview
NTUH, founded in 1895, is the teaching hospital of National Taiwan University College of Medicine and opened the National Taiwan University Cancer Center in 2019 with proton therapy. NTU investigators led the world's first national hepatitis B vaccination programme and the epidemiological studies (Ding-Shinn Chen, Mei-Hwei Chang) demonstrating its effect on hepatocellular carcinoma incidence, and its liver, lung (James Chih-Hsin Yang's EGFR trials including LUX-Lung and FLAURA), breast (Ann-Lii Cheng, Chiun-Shen Huang) and haematology groups are among Asia's most cited. Pei-Jer Chen and Ann-Lii Cheng have led global HCC trials of sorafenib, lenvatinib and atezolizumab-bevacizumab. The hospital runs Taiwan's largest cell therapy and transplant programmes and an early-phase unit.
Location
Taipei, TW
Type
hospital · National Taiwan University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#141 · 34 points (0 Newsweek + 0 NCI + 34 from 17 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to National Taiwan University Hospital, including child institutions. 746 works · 8,966 citations · 66% open access · 13% clinical trials · 2% reviews.
Oncology works per year
1522022
1662023
1582024
1482025
1222026
Most works
- Chiun‐Sheng Huang48 works
- Han‐Mo Chiu40 works
- Yen‐Shen Lu31 works
- Kun‐Huei Yeh25 works
- Ann‐Lii Cheng24 works
- Chih‐Hung Hsu24 works
- Tom Wei‐Wu Chen19 works
- Li‐Yuan Bai18 works
- Yu‐Yun Shao18 works
- James Chih‐Hsin Yang17 works
Most cited
- Hepatitis B and liver cancer
- EGFR-mutant lung cancer trials
- Proton therapy (NTU Cancer Center)
- Breast cancer
- Haematology
Ann-Lii Cheng
Distinguished Professor and Director, National Taiwan University Cancer Center
Hepatocellular carcinomaImmunotherapyAsia-Pacific trials
Taiwanese oncologist who led the Asia-Pacific sorafenib trial and co-led IMbrave150, the immunotherapy standard for liver cancer.
Chong-Jen Yu
Superintendent
PulmonologyCritical care medicineHospital leadership
Pulmonologist appointed Superintendent of National Taiwan University Hospital in August 2025, leading Taiwan's flagship academic medical centre.
Similar pages
- TrialIMbrave150
Shares Ann-Lii Cheng, VEGF / VEGFR, Atezolizumab, PD-L1.
- TrialFHND9041 Versus Afatinib for Non-small Cell Lung Cancer
Shares Afatinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
- TrialEGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
Shares Afatinib, Osimertinib, Non-small-cell lung cancer.
- TrialIMbrave050
Shares Ann-Lii Cheng, Atezolizumab, Hepatocellular carcinoma.
- Key paperIMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer
Shares Ann-Lii Cheng, VEGF / VEGFR, Atezolizumab, PD-L1.
- TargetHER4 (ERBB4)
Shares Afatinib, HER2-positive breast cancer, Non-small-cell lung cancer.
- PersonAlan P. Venook
Shares VEGF / VEGFR, EGFR, Hepatocellular carcinoma, Colorectal cancer.
- CompanyWest Japan Oncology Group
Shares Osimertinib, HER2-positive breast cancer, Small-molecule kinase inhibitors, Colorectal cancer.
cancers
fronts
technologies
targets
drugs
ApprovedSmall-molecule pan-ErbB TKI (second generation, irreversible)
Afatinib · Gilotrif / Giotrif
ApprovedMonoclonal antibody (anti-PD-L1)
Atezolizumab · Tecentriq / Tecentriq Hybreza (SC)
ApprovedSmall-molecule kinase inhibitor (EGFR)
Osimertinib · Tagrisso